Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

11.28 USD -0.29 (-2.51%)
Official Closing Price Updated: 4:04 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aldeyra Therapeu

< Previous 1 2 3 4 5 6 7 8 Next >
Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today... 
From PR Newswire
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases,... 
From PR Newswire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will... 
From PR Newswire
Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and Symptoms 
From PR Newswire
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
From PR Newswire
Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics — Research Highlights Growth, Revenue, and Consolidate
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Euronet Worldwide, Inc.... 
From GlobeNewswire News Releases
Aldeyra Therapeutics Announces Year End 2017 Financial Results
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today... 
From PR Newswire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, will issue... 
From PR Newswire
Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today... 
From PR Newswire
Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Poster Presentations to Feature Phase 2b Allergic Conjunctivitis Results, in Addition to Activity of Reproxalap and ADX-103 in Models of Retinal Inflammation, Diabetic Macular Edema, and Dry... 
From PR Newswire
New Research Coverage Highlights Carter's, Invacare, Hortonworks, BGC Partners, Hyatt Hotels, and Aldeyra Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carter's, Inc. (NYSE:CRI),... 
From GlobeNewswire News Releases
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the... 
From PR Newswire
Biotech Stocks' Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on RPRX, ALDX, NEOT, and BLRX which can be accessed for free by signing up to... 
From PR Newswire
Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
New Analyses Demonstrate Statistical Non-Inferiority of 0.5% Reproxalap Ophthalmic Solution to Corticosteroid 
From PR Newswire
Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related... 
From PR Newswire
Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related... 
From PR Newswire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 A
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 A
ADX-102 Reduces Toxic Levels of Gamma-Hydroxybutyrate and Gamma-Aminobutyrate in Brain Tissue from Knockout Mouse Model 
From PR Newswire
Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day
Dry Eye Disease Clinical Activity Correlated with Aldehyde Reduction 
From PR Newswire
Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Me
Abstract Designated Reviewers' Choice Abstract, Representing Top 10% of Submissions 
From PR Newswire
/C O R R E C T I O N -- Aldeyra Therapeutics, Inc./
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
Aldeyra Therapeutics Announces 2017 Research and Development Day
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous... 
From PR Newswire
FinancialInsiders.com Earnings Recap Week Ending September 15th, 2017
FinancialInsiders.com News Commentary 
From PR Newswire
Biotechs Ramp up Clinical Trial Programs as FDA Looks at More Efficient Drug Development Programs
MarketNewsUpdates.com News Commentary 
From PR Newswire
Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
Statistically and Clinically Significant Improvement Across Multiple Sign and Symptom Endpoints 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.